Thierry Mauvernay
President & Delegate of the Board @ Debiopharm Group
Lausanne, Switzerland
Thierry Mauvernay is a funding round investor at Debiopharm Group in Lausanne focused on Pharmaceutical and Health Diagnostics. Thierry Mauvernay is based out of Lausanne, Vaud, and is the President & Delegate of the Board of Debiopharm Group and President of Après-demain. Thierry previously worked at Innovation Scientifique Dermatologique I.S.D as a CEO. Thierry Mauvernay attended the IAE Paris, the Business School of the Sorbonne University.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Thierry Mauvernay invests in
PharmaceuticalHealth DiagnosticsEnergyMedicalGenetics
Stages Thierry Mauvernay invests in
Funding RoundSeedSeries ASeries BDebt Financing
Countries Thierry Mauvernay invests in
CanadaBelgiumSwitzerlandUnited States
Investment Focus
Industry
- Pharmaceutical 2 (25%)
- Health Diagnostics 2 (25%)
- Energy 1 (13%)
- Medical 1 (13%)
- Genetics 1 (13%)
Stage
- Funding Round 2 (25%)
- Seed 1 (13%)
- Series A 1 (13%)
- Series B 1 (13%)
- Debt Financing 1 (13%)
Country
- Canada 1 (13%)
- Belgium 1 (13%)
- Switzerland 1 (13%)
- United States 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Enerdrape
|
What if your underground parking was also a source of renewable energy for our buildings?Enerdrape turns existing underground environments into renewable sources of energy for the heating and cooling needs of buildings. We develop an architecturally integrated technology that captures both geothermal and waste heat present in underground existingenvironments, such as underground parking, tunnels, stations, and others.Our solution offers an alternative, cost-effective, and easier way to source renewable heat for heat pump systems. Enabling the energy transition and access to affordable and efficient renewable energy systems in existing urban environments. | $1.5M / Seed / Jan 11, 2024 | |
Oncomfort
|
Oncomfort’s solution for digital sedation is a completely new method for relieving patients’ pain and anxiety before, during and after medical procedures. This revolutionising digital therapy combines clinical hypnotherapy and integrative therapeutic techniques through Virtual Reality. | $11.8M / Series A / Sep 09, 2020 | |
GenePOC
|
GenePOC Inc. is a privately owned company, member of Debiopharm Group, that develops accurate and cost-effective molecular solutions to detect pathogen genes. GenePOC has developed a simple and stand-alone system for the prevention and early detection of infectious diseases based on a unique microfluidic technology. | Jan 13, 2015 | |
Immunexpress
|
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; andthe translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington. | $6M / Mar 05, 2014 | |
|
Immunexpress
|
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; andthe translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington. | Debt Financing | |
|
Immunexpress
|
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; andthe translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington. | Series B | |
|
Immunexpress
|
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; andthe translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington. | ||
|
Immunexpress
|
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; andthe translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It develops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington. |
Co-Investors
Crédit Mutuel Innovation
3 deals together
Emerillon Capital
1 deal together
WING by Digital Wallonia
1 deal together
About Debiopharm Group
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
Debiopharm Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Thierry Mauvernay
President & Delegate of the Board
|
|||
Alexandra Le Coz Sanchez
Associate Director, Private Equity Department, Debiopharm Investment S.A.
|
|||
ANGELA ZUBEL
Chief Development Officer
|
|||
Bertrand Ducrey
CEO
|
|||
Raymond Zaugg
Director, Financial department, Debiopharm Investment S.A
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Energy Investors
25,111 investors
Biotech Investors
21,775 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Energy VC Funds
20,690 investors
Biotech VC Funds
18,864 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Thierry Mauvernay invest in?
Thierry Mauvernay invests primarily in Pharmaceutical, Health Diagnostics and Energy startups, most often at Funding Round and Seed stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Thierry Mauvernay last invest?
The most recent investment recorded for Thierry Mauvernay closed in Jan 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
